PROVE-IT TIMI-22，A to Z ，RIO-EUROPE研究PPT课件.pptVIP

Topics PROVE-IT: Background PROVE-IT: Design Long-term study of antibiotic therapy against Chlamydia pneumoniae on the occurrence of cardiovascular events in patients with coronary heart disease 4162 patients with ACS (10 days) Pravastatin (40 mg daily) vs atorvastatin (80 mg daily) Patients were randomized a second time to receive treatment with either gatifloxacin 400 mg/day for a full course of 10 days per month followed by 20 days without treatment or placebo Repeated each month for two years PROVE IT-TIMI 22: CVD events by treatment group PROVE-IT: Great hope PROVE-IT: No benefit ACES: Design Study compared treatment with azithromycin 600 mg once a week for a year with placebo in 4012 patients with established coronary disease Patients were then followed for four years for the occurrence of primary end point events, any one of CHD death, nonfatal MI, coronary revascularization, or hospitalization for unstable angina RESULTS Primary end point was almost identical between the groups: 22.4% with placebo and 22.3% with azithromycin) Antibiotics in CHD PROVE-IT: 30 days PROVE-IT: Final thoughts PROVE-IT: Design Intensive and moderate lipid lowering with statin therapy after acute coronary syndrome (ACS) (N Engl J Med 2004; 350: published March 8th) 4162 patients with ACS (10 days) Pravastatin (40 mg daily) vs atorvastatin (80 mg daily) Primary end point: a composite of all-cause mortality, MI, unstable angina requiring hospitalization, revascularization, and stroke Two-year follow-up PROVE-IT: Results PROVE-IT: 30 days PROVE-IT: Understanding CRP A to Z: Design Z phase of the A to Z trial evaluating aggressive versus conservative statin therapy in 4497 ACS patients TREATMENT Early intensive treatment: Simvastatin 40 mg for one month followed by simvastatin 80 mg for the remainder of the trial Conservative treatment: Placebo for four months followed by simvastatin 20 mg for the remainder of the trial Primary end point a composit